261 related articles for article (PubMed ID: 33895262)
1. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Kandel S; Adhikary P; Li G; Cheng K
Cancer Lett; 2021 Jul; 510():67-78. PubMed ID: 33895262
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological implications of TIM3
Zhou J; Jiang Y; Zhang H; Chen L; Luo P; Li L; Zhao J; Lv F; Zou D; Zhang Y; Jing Z
Cancer Immunol Immunother; 2019 Jul; 68(7):1157-1169. PubMed ID: 31197461
[TBL] [Abstract][Full Text] [Related]
4. Tim-3 finds its place in the cancer immunotherapy landscape.
Acharya N; Sabatos-Peyton C; Anderson AC
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601081
[TBL] [Abstract][Full Text] [Related]
5. TIM3 activates the ERK1/2 pathway to promote invasion and migration of thyroid tumors.
Jin X; Yin Z; Li X; Guo H; Wang B; Zhang S; Li Y
PLoS One; 2024; 19(4):e0297695. PubMed ID: 38568917
[TBL] [Abstract][Full Text] [Related]
6. TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice.
Berckmans Y; Vankerckhoven A; Caro AA; Kempeneers J; Ceusters J; Thirion G; Vandenbrande K; Vergote I; Laoui D; Coosemans A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539483
[TBL] [Abstract][Full Text] [Related]
7. Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications.
Wang J; Wang Y; Jiang X; Xu M; Wang M; Wang R; Zheng B; Chen M; Ke Q; Long J
Cancer Lett; 2024 Apr; 588():216758. PubMed ID: 38401885
[TBL] [Abstract][Full Text] [Related]
8. Harnessing innate immune pathways for therapeutic advancement in cancer.
Hu A; Sun L; Lin H; Liao Y; Yang H; Mao Y
Signal Transduct Target Ther; 2024 Mar; 9(1):68. PubMed ID: 38523155
[TBL] [Abstract][Full Text] [Related]
9. Immune-Mediated Therapies for Liver Cancer.
Aravalli RN; Steer CJ
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28218682
[TBL] [Abstract][Full Text] [Related]
10. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.
de Mingo Pulido Á; Hänggi K; Celias DP; Gardner A; Li J; Batista-Bittencourt B; Mohamed E; Trillo-Tinoco J; Osunmakinde O; Peña R; Onimus A; Kaisho T; Kaufmann J; McEachern K; Soliman H; Luca VC; Rodriguez PC; Yu X; Ruffell B
Immunity; 2021 Jun; 54(6):1154-1167.e7. PubMed ID: 33979578
[TBL] [Abstract][Full Text] [Related]
11. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
Moskorz W; Cosmovici C; Jäger PS; Cadeddu RP; Timm J; Haas R
Br J Haematol; 2021 Jun; 193(5):941-945. PubMed ID: 33954988
[TBL] [Abstract][Full Text] [Related]
13. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N; Alotaibi AS; Bücklein V; Subklewe M
Leukemia; 2021 Jul; 35(7):1843-1863. PubMed ID: 33953290
[TBL] [Abstract][Full Text] [Related]
14. Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion.
Zhu C; Dixon KO; Newcomer K; Gu G; Xiao S; Zaghouani S; Schramm MA; Wang C; Zhang H; Goto K; Christian E; Rangachari M; Rosenblatt-Rosen O; Okada H; Mak T; Singer M; Regev A; Kuchroo V
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931442
[TBL] [Abstract][Full Text] [Related]
15. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy.
Kuang Z; Li L; Zhang P; Chen B; Wu M; Ni H; Yi S; Zou J; Liu J
Antib Ther; 2020 Dec; 3(4):227-236. PubMed ID: 33928230
[TBL] [Abstract][Full Text] [Related]
16. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation.
Dixon KO; Tabaka M; Schramm MA; Xiao S; Tang R; Dionne D; Anderson AC; Rozenblatt-Rosen O; Regev A; Kuchroo VK
Nature; 2021 Jul; 595(7865):101-106. PubMed ID: 34108686
[TBL] [Abstract][Full Text] [Related]
17. TIM-3: An update on immunotherapy.
Zhao L; Cheng S; Fan L; Zhang B; Xu S
Int Immunopharmacol; 2021 Oct; 99():107933. PubMed ID: 34224993
[TBL] [Abstract][Full Text] [Related]
18. The regulation of immune checkpoints by the hypoxic tumor microenvironment.
Hu M; Li Y; Lu Y; Wang M; Li Y; Wang C; Li Q; Zhao H
PeerJ; 2021; 9():e11306. PubMed ID: 34012727
[TBL] [Abstract][Full Text] [Related]
19. Leukemic Stem Cell (CD34
Mohamed MMI; Aref S; Agdar MA; Mabed M; El-Sokkary AMA
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):508-513. PubMed ID: 33931379
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
Klein O; Kee D; Markman B; Carlino MS; Underhill C; Palmer J; Power D; Cebon J; Behren A
Cancer Cell; 2021 May; 39(5):592-593. PubMed ID: 33930312
[No Abstract] [Full Text] [Related]
[Next] [New Search]
